CGEM · NASDAQ

Cullinan Therapeutics, Inc.

Q: How do I get CGEM news from the API?

Call GET /v1/news?tickers=CGEM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

$15.81 +0.23 (+1.48%)

Company overview

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in developing oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016, and is headquartered in Cambridge, MA.

Sector: Healthcare
Industry: Medical - Pharmaceuticals
Exchange: NASDAQ
Market cap: $972M
Employees: 111
Headquarters: Cambridge, MA
Website: cullinantherapeutics.com
CEO: Nadim Ahmed
Listed: January 8, 2021
P/E: -4.21
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: -$79,000
Operating income: -$240M
EBITDA: -$235M
Net income: -$221M
EPS: -$3.75
Total assets: $403M
Total debt: $2.4M
Earnings yield: -23.73%

Price chart

CGEM 1D NASDAQ O14.93H15.60L14.74C15.58+0.74 (+4.98%)Vol187.60K

News

Ticker	Type	Headline	Source	Published
CGEMCullinan Therapeutics, Inc.	Stock news	Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?	Zacks Investment Research	Oct 29, 10:55:58 AM ET
CGEMCullinan Therapeutics, Inc.	Stock news	3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead	MarketBeat	Oct 28, 9:46:59 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA	GlobeNewswire	Oct 27, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases	Business Wire	Oct 19, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia	GlobeNewsWire	Oct 8, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Stock news	New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program	GlobeNewsWire	Oct 1, 7:30:00 PM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases	Seeking Alpha	Sep 29, 7:30:42 AM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049	MarketBeat	Sep 28, 7:02:26 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio	GlobeNewsWire	Sep 24, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum	GlobeNewsWire	Sep 21, 12:00:00 PM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript	Seeking Alpha	Sep 14, 12:31:41 PM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer	GlobeNewsWire	Sep 14, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer	GuruFocus	Sep 13, 8:00:00 PM ET
CGEMCullinan Therapeutics, Inc.	Press release	Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer	Business Wire	Sep 13, 7:15:00 PM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer	GlobeNewswire	Sep 10, 1:00:00 PM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset	Seeking Alpha	Aug 26, 5:41:12 AM ET
CGEMCullinan Therapeutics, Inc.	Stock news	Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape	Benzinga	Aug 13, 11:21:45 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results	GlobeNewsWire	Aug 6, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager	GlobeNewsWire	May 26, 7:00:00 AM ET
CGEMCullinan Therapeutics, Inc.	Press release	Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress	GlobeNewsWire	May 18, 5:00:00 PM ET

FAQ

Questions about Cullinan Therapeutics, Inc.

What does Cullinan Therapeutics, Inc. do?

What is CGEM's market cap?

Cullinan Therapeutics, Inc. (CGEM) is a listed stock with a live quote. The latest market cap on this page is $972M.

Where is Cullinan Therapeutics, Inc. headquartered?

Cullinan Therapeutics, Inc. is headquartered in Cambridge, MA.

How do I get CGEM news from the API?

Call GET /v1/news?tickers=CGEM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

How far back does CGEM news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CGEM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.

Is the CGEM price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs